PHILADELPHIA—At ACR Convergence 2022, the much-anticipated ACR Review Course featured talks from eight experts. Topics reflected the heterogeneity of our field and included Sjögren’s disease, spondyloarthritis (SpA), osteoarthritis (OA), paraneoplastic rheumatic syndromes, metabolic bone disease, statin myopathy, Raynaud’s phenomenon and autoinflammatory syndrome. Here, I share highlights from this comprehensive, six-hour session. Sjögren’s Disease Sara S….
PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…
PHILADELPHIA—Treat to target (T2T) is a common phrase in rheumatology these days—and a welcome one.1 Many of us are familiar with what T2T means in rheumatoid arthritis (RA), but we may be less sure of its meaning in axial spondyloarthritis (axSpA). At ACR Convergence 2022, Alexis Ogdie, MD, associate professor of medicine and epidemiology, University of…
ORLANDO—Despite the COVID-19 pandemic, the past two years have been exciting for rheumatology providers and patients. We’ve seen the U.S. Food & Drug Administration (FDA) approve new therapies and expand indications for established drugs. At the 2022 ACR Education Exchange, Jeffrey Curtis, MD, MS, MPH, Marguerite Jones Harbert-Gene Ball Endowed professor of medicine, Division of…
The ACR’s Committee on Rheumatology Training & Workforce Issues helps young rheumatologists to become successful and find meaning in their work. Here is an update on the committee’s most recent accomplishments.
The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…
ACR Convergence 2021—On Nov. 5, Karen H. Costenbader, MD, MPH, professor of medicine, Harvard Medical School, and director of the lupus program, Brigham and Women’s Hospital, Boston, gave a whirlwind review of the most important clinical rheumatology publications of the past year. Testing New Medications for Rheumatic Disease ADVOCATE Trial of Avacopan Dr. Costenbader first…
SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…
Experts provide insights into spondyloarthropathy, temporomandibular joint involvement and imaging for pediatric patients with JIA.
Laura Coates, MBChB, MRCP, PhD, described & compared the intricacies of different outcome measures, as well as implications for clinical practice & trials, for patients with psoriatic arthritis.